HEB - Hemispherx Biopharma, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.8000
-0.0100 (-0.55%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close1.8100
Open1.9700
Bid0.0000 x 900
Ask0.0000 x 800
Day's Range1.8000 - 1.9000
52 Week Range1.5100 - 14.9600
Volume14,684
Avg. Volume98,191
Market Cap4.542M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.20
Trade prices are not sourced from all markets
  • GlobeNewswire

    Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), today announced that it has changed its name to AIM ImmunoTech Inc. effective September 3, 2019. Additionally, the Company announced that effective September 3, 2019, the Company’s ticker will change to “AIM.” The Company’s common stock will continue to trade on the NYSE American.

  • GlobeNewswire

    Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the second quarter, which ended June 30, 2019, and provides a business update.

  • Is Hemispherx Biopharma, Inc.'s (NYSEMKT:HEB) CEO Pay Justified?
    Simply Wall St.

    Is Hemispherx Biopharma, Inc.'s (NYSEMKT:HEB) CEO Pay Justified?

    Thomas Equels has been the CEO of Hemispherx Biopharma, Inc. (NYSEMKT:HEB) since 2016. First, this article will...

  • GlobeNewswire

    Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

    Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovarian cancer in its Phase 1 trial using Ampligen with Intron A and celecoxib. The research team, led by Drs. Robert Edwards, Anda Vlad and Brian Orr, found that Ampligen was well tolerated on an intraperitoneal basis and as a combination therapy. “This concludes that these drugs can be given in this combination with no major toxicities noted and no evidence of added toxicity when adding the immunomodulators to cisplatin as most of the grade 3 toxicities listed above are common with cisplatin,” wrote Dr. Orr in the Phase 1 report.

  • GlobeNewswire

    Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing

    Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI algorithms following the filing of an 8-K on July 22, 2019. The two stock news organizations, Sagient Research and StreetAccount, both misreported that the company was raising $70 million in an Equity Distribution Agreement when, actually, the company was simply renewing a prior EDA that was related to an ATM and making the requisite SEC filings to raise up to $4.5 million under the new EDA, the maximum permitted at this time.

  • GuruFocus.com

    5 Immunotherapy Stocks to Keep a Close Eye On

    Immunotherapy is changing the face of cancer treatment as we know it, creating compelling investment opportunities

  • ACCESSWIRE

    Hemispherx Biopharma, Inc. Discusses Clinical Development and Competitive Advantage in New SNNLive Video Interview on StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / July 2, 2019 / StockNewsNow.com , The Official MicroCap News Source ™ , today published an SNNLive Video Interview with Thomas Equels, CEO of Hemispherx Biopharma, Inc. (NYSE ...

  • GlobeNewswire

    Hemispherx Biopharma CFO Adam Pascale Announces Retirement

    Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after nearly a quarter century with the company. Pascale joined Hemispherx in 1995 as an accounting manager, rising to the position of Chief Accounting Officer before being named CFO in 2016. Pascale has been an integral part of Hemispherx’s leadership team since being named CFO, helping to execute CEO Thomas K. Equels’ long-term business plan to test the company’s lead product Ampligen in the treatment of cancer.

  • GuruFocus.com

    Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. ...

    Exec. Vice Chairman/CEO/Pres. of Hemispherx Biopharma Inc (HEB) Thomas K. Equels bought 29,404 shares of HEB on 06/21/2019 at an average price of $4.03 a share.

  • Have Insiders Been Buying Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Shares?
    Simply Wall St.

    Have Insiders Been Buying Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • GlobeNewswire

    Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program

    Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of existing cancer immunotherapies, such as checkpoint blockade therapies. The company has five ongoing immuno-oncology clinical trials, four planned clinical trials and an active Early Access Program (EAP). The most recent addition to the ongoing group is a clinical study in the treatment of prostate cancer, where FDA authorization has been received.

  • Company News For Jun 13, 2019
    Zacks

    Company News For Jun 13, 2019

    Companies in the news are: PLAY, NEPT, TGODF, RGS, GOOGL and HEB

  • How Does Investing In Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Impact The Volatility Of Your Portfolio?
    Simply Wall St.

    How Does Investing In Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Impact The Volatility Of Your Portfolio?

    If you're interested in Hemispherx Biopharma, Inc. (NYSEMKT:HEB), then you might want to consider its beta (a measure...

  • GlobeNewswire

    Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin

    OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) (See: https://clinicaltrials.gov/ct2/show/NCT03734692). On receipt of information from clinical sites, it is Hemispherx’ policy to provide periodic updates when a clinical study (1) is FDA authorized, (2) begins enrollment, (3) treats its first subject, (4) issues material interim reports and (5) releases final results. The company is pleased to announce this step in our clinical program, which constitutes steady progress toward Hemispherx’ clinical goals.

  • GlobeNewswire

    Hemispherx Biopharma Stockholders Approve Reverse Stock Split

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today announced that its stockholders voted in favor to grant the Board of Directors the authority to effect a reverse stock split of the company’s issued and outstanding shares of Common Stock. The proposal passed by approximately 55% of all issued and outstanding shares and approximately 86% of the shares actually voted were voted in favor of the reverse split. Following the stockholder vote, the Board met and approved a 1-for-44 reverse stock split to achieve a value of approximately $5 per share.

  • GlobeNewswire

    Hemispherx Reports 2019 First Quarter Financial Results

    OCALA Fla., May 16, 2019 -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple.

  • GlobeNewswire

    Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma

    ORLANDO, FL, May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced it is making progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer. According to the latest news from the company, Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy.

  • GlobeNewswire

    Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

    Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer. Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy.

  • GlobeNewswire

    Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology

    OCALA, Fla., May 08, 2019 -- (NYSE American: HEB) — Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet.

  • GlobeNewswire

    Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

    Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases — and whose product portfolio includes Ampligen, commercially approved in Argentina, as the world’s only approved therapeutic for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) — announced today that the impressive results from a blood-based, real-time diagnostic test out of Stanford University demonstrates an ability to identify moderate to severe ME/CFS patients from normal controls. While Hemispherx is currently focused on Ampligen in the treatment of cancer, for which there are multiple ongoing trials, regulatory approval of Ampligen in the treatment of ME/CFS in the United States is also a corporate goal.

  • ACCESSWIRE

    Hemispherx To Be Transparent on the Development of Ampligen and Announced Significant Progress

    NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report ...

  • GlobeNewswire

    Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program

    OCALA, Fla., April 30, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today significant progress in its Ampligen recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) under the leadership of the principal investigator, Robert Edwards, MD. The ovarian cancer program is being funded in part by an Ovarian Cancer Specialized Program of Research Excellence (SPORE) from the National Institutes of Health (NIH), which is supporting a Phase 1/2 study of intraperitoneal chemo-immunotherapy in recurrent ovarian cancer.

  • GlobeNewswire

    Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019

    Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today that CEO Thomas K. Equels will present at the Planet MicroCap Showcase on Wednesday, May 1, 2019, at 8:30 a.m. PT. Equels' presentation will focus on the company’s ongoing clinical trials and programs using its flagship investigational drug Ampligen to treat multiple cancer types. The company recently announced significant progress in its Ampligen pancreatic cancer program and multiple Ampligen plus checkpoint blockade immuno-oncology programs.

  • ACCESSWIRE

    MicroCap Review Magazine Spring 2019 Issue Now Available

    The Digital Issue of the Spring 2019 MicroCap Review Magazine,The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / April 23, 2019 / SNN ...